Clinical trials: Alcohol Disorders
Acute on Chronic Hepatic Failure, Acute Liver Failure
Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF
The study will evaluate the pharmacokinetics, pharmacodynamics, safety and preliminary efficacy of IDN-6556 in subjects with cirrhosis of the liver who are hospitalized for more than 24 hours due to acute deterioration of liver…
- Conditions
- Acute on Chronic Hepatic Failure, Acute Liver Failure, Liver Cirrhosis, Acute Alcoholic Hepatitis
- Trial name
- NCT01937130
- Testing
- IDN-6556
- Where
- 26 sites in United States, United Kingdom
- Volunteers
- 23 people
- Sponsor
- Conatus Pharmaceuticals Inc.
Erectile Dysfunction
Effect of Moderate Alcohol on Absorption and Onset of Hezkue Sildenafil Suspension
This is a Phase 2, open-label, randomized crossover study assessing the effect of moderate alcohol intake on the absorption and onset of action of Hezkue® sildenafil oral suspension in adult subjects.
- Trial name
- NCT07290400
- Testing
- Hezkue Sildenafil Oral Suspension, Moderate Alcohol Intake
- Volunteers
- 36 people
- Sponsor
- Aspargo Labs, Inc
Acute Liver Failure
Registry Protocol for Tracking Trial Subjects After VTI-206 Study Completion
VTI-207 (NCT01452295) is designed to follow subjects, both treated and control, for five years after their completion of study participation in protocol VTI-206 (NCT00973817) to gather information relating to the incidence of…
- Trial name
- NCT01452295
- Testing
- ELAD (Extracorporeal Liver Assist System)
- Sponsor
- Vital Therapies, Inc.
Alcohol Abuse, Drug Abuse
A Web App for Patients With Alcohol and Drug Use Problems in Primary Care
The objective of this pilot study is to evaluate the feasibility and technical merit of a web application for patients in primary care called Check-up and Choices (CC).
- Trial name
- NCT01830114
- Testing
- Web app
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Behavior Therapy Associates, LLP
Alcohol Use Disorder, Alcohol Abuse
tAN for Substance Use Disorder
The study will involve a 5-day tAN treatment to attenuate alcohol withdrawal syndrome (AWS) and alter resting state functional connectivity (RSFC) between OFC and striatum in patients with alcohol use disorder (AUD).
- Conditions
- Alcohol Use Disorder, Alcohol Abuse, Substance Use Disorders, Substance Use Disorders Alcohol Use Withdrawal State
- Trial name
- NCT07281261
- Testing
- Sparrow Ascent
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Spark Biomedical, Inc.
Alcohol Use Disorder
Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter Polymorphisms
Randomized, multi-center, double-blind, parallel-group, placebo-controlled study. Eligible subjects will be randomized to receive either 0.33 mg AD04 or placebo orally twice-daily for 24 weeks in conjunction with brief…
- Trial name
- ONWARD (NCT04101227)
- Testing
- AD04 (ondansetron), Companion Diagnostic for Genetic Testing, Brief Psychological Counseling
- Where
- 25 sites in Bulgaria, Croatia and 5 more
- Volunteers
- 302 people
- Sponsor
- Adial Pharmaceuticals
Alcohol Use Disorder
Acamprosate Initiated During Alcohol Detoxification
Acamprosate is approved by the Food and Drug Administration (FDA) for the treatment of alcoholism. The purpose of this study is to see if initiating acamprosate early in alcohol detoxification instead of waiting until…
- Trial name
- NCT00360594
- Testing
- Acamprosate
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Forest Laboratories
Alcohol Dependence
Safety and Efficacy of Nalmefene in Patients With Alcohol Dependence
The purpose of the study is long-term safety, tolerability and efficacy of nalmefene in patients with alcohol dependence.
- Trial name
- SENSE (NCT00811941)
- Testing
- Nalmefene
- Where
- 60 sites in Czechia, Estonia and 8 more
- Volunteers
- 665 people
- Sponsor
- H. Lundbeck A/S
Alcohol Dependence
Effects of Nalmefene After Single Dose on the Blood Oxygen Level Dependent (BOLD) fMRI Signal in the Ventral Striatum to Reward Responding in the Monetary Incentive Delay Task (MIDT), in Non-treatment Seeking Subjects With Alcohol Dependence Following Alcohol Challenge
To contribute to the understanding of the underlying neurobiological mechanism behind the interaction of alcohol and nalmefene
- Trial name
- NCT01969617
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- H. Lundbeck A/S
Alcohol Abuse, Alcohol Dependence
Remote Brief Intervention and Referrals to Treatment Service for Alcohol
The traditional paradigm that relies upon training physicians and nurses or uses on-site interventionists to perform screening, brief intervention, and referral to treatment (SBIRT) for alcohol has proven unsustainable in most…
- Trial name
- RBIRT (NCT02622984)
- Testing
- RBIRT, SBIRT
- Where
- United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Polaris Health Directions
Alcoholism
Study of Aripiprazole in Subjects With Alcoholism
The purpose of this clinical research study is to learn whether subjects treated with aripiprazole are able to abstain from alcohol use for a greater number of days than subjects treated with placebo.
- Trial name
- NCT00082199
- Testing
- Aripiprazole
- Where
- 14 sites in United States
- Volunteers
- 400 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Motivational Interviewing, Alcohol Use Disorder
ClientBot: a Conversational Agent That Supports Skills Practice and Feedback for Motivational Interviewing
This multi-stage study includes qualitative interviews, usability research, and a randomized training study of technology implementation in a real-world clinical setting.
- Trial name
- NCT05479890
- Testing
- ClientBot
- Where
- United States
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Lyssn.io, Inc.
Substance-related Disorders, Alcohol and Other Substance Use Prevention
Evaluating Feasibility, Acceptability, Usability, and an Initial Estimate of Effect of a Novel Training Platform on Peer Recovery Supporter Skill, Adherence, and Knowledge Gain-Phase I
This pilot study evaluates the feasibility, usability, and acceptability of the Thrive Digital Peer Platform (TDPP), an online training system for Peer Recovery Support Specialists (PRSS).
- Conditions
- Substance-related Disorders, Alcohol and Other Substance Use Prevention, Alcohol and Other Drug Use Disorders
- Trial name
- NCT07090590
- Testing
- Thrive Digital Peer Platform (TDPP)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Thrive Digital Health, LLC
Alcohol Use Disorder (AUD)
Evaluate the Efficacy and Safety of Naltrexone Hydrochloride Implant in Patients With Alcohol Use Disorder
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial. The study plans to enroll 240 adult patients with Alcohol Use Disorder (AUD).
- Trial name
- AUD (NCT07433413)
- Testing
- Naltrexone
- Volunteers
- 240 people
- Sponsor
- Shenzhen Sciencare Medical Industries Co., Ltd.
Alcohol Associated Hepatitis
FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study
The purpose of this trial is to assess dose related safety, efficacy, and pharmacokinetics (PK) of INT-787 in participants with severe alcohol-associated hepatitis (sAH).
- Trial name
- FRESH (NCT05639543)
- Testing
- INT-787
- Where
- 29 sites in United States, France and 1 more
- Volunteers
- 67 people
- Sponsor
- Intercept Pharmaceuticals
Primary Liver Cancer
Polyvinyl Alcohol Embolization Microspheres
To evaluate the safety and efficacy of polyvinyl alcohol embolization microspheres developed and manufactured by Shanghai Huihe Medical Technology Co., LTD.
- Trial name
- NCT05770635
- Testing
- Embosphere and chemotherapy drug, Polyvinyl alcohol embolization microspheres (Huihe Medical) and chemotherapy drug
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Shanghai Huihe Medical Technology Co., Ltd
Substance Abuse, Criminal Behavior
Swift, Certain, and Fair: Reducing Recidivism and Improving Outcomes for Alcohol and Drug Users on State Parole
This research project will study the outcomes of medium- to high-risk parolees with a history of substance abuse in Alleghany County, Pennsylvania supervised under Swift-Certain-Fair parole.
- Trial name
- NCT03826420
- Testing
- SCF Supervision with Secure Confinement Sanctioning, SCF Supervision with Work Release Sanctioning, SCF Supervision with GPS Supervision Sanctioning
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Botec Analysis, LLC
Substance Use Disorders, Alcohol Use Disorders
DEVELOPMENT OF A NOVEL PEER RECOVERY SUPPORTER TRAINING PLATFORM
This study tests an online training platform for peer recovery support specialists, people in recovery who support others with alcohol and other substance use problems.
- Conditions
- Substance Use Disorders, Alcohol Use Disorders, Recovery Support Services, Peer Recovery Coaching
- Trial name
- NCT07044531
- Testing
- Training-as-Usual (TAU), TDPP-A (Asynchronous Platform), TDPP-Z (Hybrid)
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- Thrive Digital Health, LLC
Alcohol, Phosphodiesterase Inhibitor
A Study of the Hemodynamic Interactions of TPN171H Tablets & Alcohol in Healthy Male Subjects
The purpose of this study is primarily to evaluate the effects of taking TPN171H tablets with alcohol on blood pressure, pulse,and pharmacokinetic in Chinese healthy male subjects.
- Conditions
- Alcohol, Phosphodiesterase Inhibitor, Erectile Dysfunction
- Trial name
- NCT05316428
- Testing
- TPN171H tablet plus alcohol, alcohol, TPN171H tablet
- Where
- China
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Alcohol Dependence
A Study of MK0594 in Patients With Alcohol Dependence (0594-020)
A study in patients with alcohol dependence to see if MK0594 is safe and effective in maintaining absence of heavy drinking over a 12-week treatment period.
- Trial name
- NCT00835718
- Testing
- Comparator: MK0594 5 mg/day, Comparator: MK0594 1 mg/day, Comparator: MK0594 1 mg/week
- Volunteers
- 162 people
- Sponsor
- Vyne Therapeutics Inc.